Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms
Abstract
Simple Summary The classical BCR::ABL1 negative myeloproliferative neoplasms (MPN) are predominantly driven by mutations in three genes: JAK2, CALR, and MPL. Detection and quantitation of these mutations is important for disease diagnosis and monitoring. This review explores molecular methods used to monitor measurable residual disease (MRD) in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) by tracking these mutations. Polymerase chain reaction (PCR)-based tests have been widely adopted, while emerging techniques like droplet digital PCR (ddPCR) can detect extremely low levels of mutations with high accuracy. Next-generation sequencing (NGS) provides a broader insight into genetic changes, helping identify additional mutations linked to disease progression or treatment resistance. Improvements in sensitivity are likely to further the use of NGS approaches for MRD monitoring. These evolving methods will allow for greater scope for disease monitoring in the setting of established and novel emerging therapeutic modalities.